Pada Penelitian ini membahas implementasi penjaminan obat alteplase pada stroke iskemik di RS Tipe B pada tahun 2023, sesuai dengan PMK No. 3 Tahun 2023. Penelitian dilakukan di RS Tipe B di DKI Jakarta. Tujuan penelitian adalah mengetahui implementasi penjaminan obat alteplase Tahun 2023, menggunakan pendekatan kualitatif non-eksperimental Edward III. Hasil penelitian menunjukkan implementasi berjalan dengan baik, meskipun terdapat perbedaan dalam penentuan onsite stroke antara PNPK Stroke dan Fornas. Persiapan sarana, prasarana, dan tim code stroke menjadi krusial. Di RS S, tim code stroke tersedia sejak pertengahan 2023 dan trombolisis dimulai pada Oktober 2023. Di RS P, trombolisis dimulai pada Februari 2024 setelah persiapan intens mulai November 2023. Tantangan utama adalah kurang siapnya pelaksana (tim Code Stroke) sejak dimulainya penjaminan obat alteplase dan RS yang belum dilengkapi CT-Scan. Dari 2.218 RS, 82 RS mengajukan klaim obat alteplase (3,70%) dengan 774 kasus klaim (0,24%) dari 322.282 kasus stroke iskemik. Kesimpulannya, implementasi penjaminan obat alteplase di RS yang diteliti terbilang tidak ada kendala disisi penjaminan, namun masih diperlukan sosialisasi ke RS. Selain itu diperlukan persiapan dari sisi pelaksanaan tindakan trombolisis seperti SDM, sinkronisasi kebijakan, dan persiapan yang lebih baik di RS untuk optimalisasi trombolisis. Rekomendasi mencakup revisi kebijakan, penyusunan buku pedoman Tim Code Stroke, dan penggunaan aplikasi stroke registry serta program ECHO untuk sosialisasi dan pelatihan yang lebih baik.

This study discusses the implementation of alteplase drug assurance for ischemic stroke in Type B Hospitals in 2023, in accordance with PMK No. 3 of 2023. The research was conducted at a Type B Hospital in DKI Jakarta. The aim of the study is to understand the implementation of alteplase drug assurance in 2023, using a non-experimental qualitative approach by Edward III. The results indicate that the implementation is proceeding well, although there are differences in the determination of onsite stroke between PNPK Stroke and Fornas. The preparation of facilities, infrastructure, and the code stroke team is crucial. At RS S, the code stroke team has been available since mid-2023, and thrombolysis began in October 2023. At RS P, thrombolysis started in February 2024 after intensive preparation from November 2023. The main challenge is the unpreparedness of the implementing team (Code Stroke team) since the commencement of alteplase drug assurance and hospitals not yet equipped with CT-Scans. Out of 2,218 hospitals, 82 hospitals submitted claims for alteplase drugs (3.70%) with 774 claim cases (0.24%) out of 322,282 ischemic stroke cases. In conclusion, the implementation of alteplase drug assurance in the studied hospitals does not face any issues from the assurance side, but further socialization to hospitals is needed. Additionally, preparation is required in terms of thrombolysis actions such as human resources, policy synchronization, and better preparation at hospitals for optimal thrombolysis. Recommendations include policy revisions, preparation of a Code Stroke Team handbook, and the use of stroke registry applications and the ECHO program for better socialization and training.